Comparative measurement of CNP and NT-proCNP in human blood samples: a methodological evaluation

Andreas Kuehnl, Jaroslav Pelisek, Martin Bruckmeier, Wajima Safi and Hans-Henning Eckstein*

Abstract

Background: C-type natriuretic peptide (CNP) has anti-inflammatory, anti-proliferative, and anti-migratory properties. During the past years, CNP has attained an increasing interest by many research groups, especially in the cardiovascular field. Nevertheless, still no reliable data exist on the difference of CNP concentration between serum and plasma samples. Also, the influence of delayed blood sample proceeding is unknown. The aim of this study was to investigate the difference of CNP and NT-proCNP concentrations between serum and plasma samples. In order to identify potential methodological bias, this study should also validate the stability of CNP and NT-proCNP in full blood samples stored at room temperature.

Findings: Triplets (serum, plasma, full blood) of fasting blood samples from 12 healthy male individuals were collected. Analysis of CNP and NT-proCNP concentration was performed immediately following sampling, and after 30 minutes or 2 hours of storage at room temperature. Mean serum concentrations at baseline were 0.997 ± 0.379 ng/ml for CNP and 58.5 ± 28.3 pg/ml for NT-proCNP. Furthermore, NT-proCNP concentration did not change significantly during the allotted time and did not differ between serum, plasma, and full blood samples. At baseline, concentrations of CNP were significantly different between samples containing either sodium-citrate or EDTA as a clotting inhibitor (1.933 ± 0.699 ng/ml vs. 0.991 ± 0.489 ng/ml, p = 0.001).

Conclusions: CNP and NT-proCNP are stable for at least two hours, even when sample processing is delayed or blood probes are stored at room temperature. NT-proCNP assay demonstrated more consistent and reliable data and should therefore be preferred for usage in clinical applications. Nevertheless, as recommended for ANP and BNP, immunoassays for CNP should also be standardized or harmonized in the future.

Keywords: CNP, NT-proCNP, Sample processing

Findings

Introduction

C-type natriuretic peptide (CNP), identified in 1990 by Sudoh et al., is the most ancient member of the natriuretic peptide family [1]. CNP selectively stimulates the human natriuretic peptide receptor 2 (NPR2), which activates the cGMP-dependent kinase (cGK) by elevating intracellular concentration of cGMP [2]. In addition, CNP binds NPR3 and in turn deactivates protein kinase A by G protein-dependent inhibition of adenylyl cyclase [3]. CNP has anti-proliferative and anti-migratory properties [4] and was also identified as an endothelium derived relaxing factor [5]. Furthermore, CNP inhibits neointimal restenosis, reduces vascular constrictive remodeling and cardiac ischemia-reperfusion injury [6,7]. CNP plays an important role in bone growth, reproduction, nerve growth, re-endothelialisation, as well as renal, pancreatic, and cardiac function [2,3]. In addition, CNP has recently been recognised to be involved in the development of atherosclerotic plaque formation [8,9].

Due to the plethora of CNP functions, this peptide has attained increasing interest in cardiovascular research during the past years. However, studies concerning CNP concentrations in blood samples are inconsistent. Some of these studies measured concentrations of CNP or its amino-terminal pro-peptide (NT-proCNP) in serum...
samples and others used plasma samples [10-22]. Unfortunately, details on potential delays during blood sampling and subsequent sample processing have not yet been reported. In the available literature thus far, no data exist on the difference of CNP/NT-proCNP concentrations between serum and plasma samples. Also, the influence of the delay of blood sample processing remains unclear. In addition, CNP concentration in serum and plasma samples varied markedly (Table 1). Therefore, the aim of this study was to answer the following methodological questions: (1) Does delayed processing of the blood samples stored at room temperature cause

Table 1 Overview of the reported baseline blood concentrations of CNP and NT-proCNP (mean ± SD)

| Author, year | Age | n | Subgroup | CNP (pg/ml) | NT-proCNP (pg/ml) |
|--------------|-----|---|----------|-------------|-------------------|
| Del Ry, 2012 [11] | 0-3d | 41 | newborns | 11.6 ± 2.1*<R> | |
| | 4-30d | 24 | newborns | 16.4 ± 3.7*<R> | |
| | 1-12 m | 22 | infants | 15.4 ± 2.7*<R> | |
| | 1-12 | 32 | childrens | 13.6 ± 2.3*<R> | |
| | 64 ± 1 | 32 | healthy adults | 7.4 ± 1.0*<R> | |
| Del Ry, 2011 [10] | 64 ± 1 | 130 | heart failure | 7.86 ± 0.41*<R> | 67.1 ± 7.36 |
| | 63 ± 2 | 19 | diabetes | 8.70 ± 1.62*<R> | 51.5 ± 5.75 |
| | 52 ± 1 | 24 | liver cirrhosis | 4.97 ± 0.55*<R> | 78.4 ± 19.9 |
| | 61 ± 2 | 73 | healthy | 2.35 ± 0.11*<R> | 45.5 ± 1.84 |
| Olewicz-Gawlik, 2010 [17] | 60 ± 15 | 40 | RA | 105 ± 189 |
| | | | healthy | 50 ± 35 |
| Vlachopoulos, 2009 [21] | 57 ± 10 | 52 | erectile dysfunction | 2.28 ± 0.87 |
| | | | healthy | 3.70 ± 0.76 |
| Palmer, 2009 [19] | 64 ± 9 | 120 | cardiovascular disease | 1.43*<R><Ra> | 187.0*<Ra> |
| Dietmann, 2008 [14] | 0.8-36 | 50 | Malaria, severe | 120 ± 72 |
| | 0.8-20 | 39 | Malaria, uncomplicated healthy | 1250.0 ± 49 |
| | 0.8-64 | 25 | | 155 ± 70 |
| Yagci, 2008 [22] | 34 ± 6 | 26 | healthy | 800 ± 270*<E> |
| | 34 ± 9 | 28 | Behcet, active | 490 ± 120*<E> |
| | | | Behcet, inactive | 650 ± 200*<E> |
| Del Ry, 2007 [12] | 62 ± 2 | 51 | ILVD | 7.0 ± 0.9*<R> | |
| | 61 ± 2 | 60 | healthy | 2.5 ± 0.12*<R> | |
| Olney, 2007 [18] | 13 ± 2 | 10 | GHD baseline | 339 ± 40 |
| | | | GHD under therapy | 622 ± 157 |
| | | | healthy | 432 ± 64 |
| Lupattelli, 2006 [16] | 35-60 | 44 | Hyperlipidemia | 4100 ± 5800*<E> | |
| | | | healthy controls | 5700 ± 3300*<E> | |
| Del Ry, 2005 [13] | 61 ± 2 | 21 | healthy | 2.7 ± 0.2*<R> | |
| Prickett, 2001 [20] | 33 - 91 | 22 | heart failure | 105 ± 5.4 |
| | 25 - 55 | 16 | healthy | 80 ± 3.2 |
| Gülberg, 2000 [15] | 57 ± 2 | 20 | liver cirrhosis, RI | 2.7 ± 0.4*<R> | |
| | 52 ± 2 | 20 | liver cirrhosis, no RI | 3.0 ± 0.2*<R> | |
| | 45 ± 6 | 11 | healthy | 4.2 ± 0.4*<R> | |
| present study | 29 ± 2 | 12 | healthy | 997 ± 379*<E> | 991 ± 489*<E> |
| | | | | 58.5 ± 28.3 | 60.3 ± 23.9 |
| | | | | 1933 ± 699°<E> |

At baseline, CNP concentrations are measured in blood samples anticoagulated either with EDTA(*) or sodium-citrate (*). Concentration of CNP was measured either with RIA-assay (R) or ELISA-assay (E). Unless otherwise indicated (d = days, m = months), age is given in years. a = arterial blood sample, CVRF = cardiovascular risk factors, RA = rheumatoid arthritis, ILVD = idiopathic left ventricle dysfunction, RI = renal insufficiency, GHD = growth hormone deficiency.
bias? (2) Is there any difference between serum and plasma concentrations of CNP or NT-proCNP? (3) Are these differences time dependent?

Methods
We studied 12 male volunteers (mean age 29 ± 2 years, normal weight, no drug therapy, no history of cardiovascular or other diseases, 3 smokers). From all investigated subjects informed consent was obtained. Triplets of fasting blood samples were taken from all volunteers at 8 o’clock in the morning. Blood samples were collected using the 7.5 ml S-Monovette® collection system (Sarstedt, Nümbrecht, Germany) containing either clotting activator (Kaolin) for serum samples, sodium-citrate for plasma samples or Potassium–EDTA for full blood samples. All samples for baseline analyses were immediately centrifuged at 2,000 × g for 10 min at 4°C and supernatant was stored at −70°C until analysis. For midterm analyses (30 minutes or 2 hours), plasma samples were centrifuged at 2,000 × g for 10 min at room temperature. Supernatant was removed and stored at room temperature for 30 min or 2 hours. Following blood clotting, serum samples were processed identically to plasma samples. Supernatant was saved and also stored at room temperature for 30 min or 2 hours. Full blood samples were stored at room temperature without centrifugation. After 30 min or 2 hours, full blood samples were centrifuged at 2,000 × g for 10 min at 4°C. Supernatant was removed and stored at −70°C until analysis. The concentration of CNP was measured using the CNP-22 EIA Kit (#EK-012-03, Phoenix Pharmaceuticals, Karlsruhe, Germany) according to the manufacturer’s protocol. NT-proCNP concentration was measured using the NT-proCNP EIA Kit (Biomedica, Vienna, Austria) according to the manufacturer’s protocol. One-way ANOVA was used for comparison between groups. For pairwise comparisons, the t-test was applied. Data are shown as means ± standard deviation (SD) or 95% confidence interval (95%-CI). Statistical significance was assumed at p < 0.05. Data were analyzed using MedCalc® for Windows, Version 10.0.1.0 (MedCalc Software, Mariakerke, Belgium).

Results
As shown in Figure 1a, baseline concentrations of CNP in serum, plasma, and full blood samples were 0.997 ± 0.379 ng/ml, 1.933 ± 0.699 ng/ml, and 0.991 ± 0.489 ng/ml, respectively. Plasma concentrations of CNP were significantly higher compared to serum and full blood samples at all time points (ANOVA, p = 0.001 at baseline, p < 0.001 at 30’ min. and p = 0.003 at 120’ min.). No significant difference was observed between serum and full blood samples at any time point (ANOVA, p > 0.05). Baseline concentrations of NT-proCNP in serum, plasma, and full blood samples were 58.5 ± 28.3 pg/ml, 60.3 ± 23.9 pg/ml, and 50.7 ± 21.4 pg/ml, respectively (Figure 1b). No significant difference was found between the groups at any time point (ANOVA, p > 0.05). In full blood samples, concentration of lactate increased significantly after 2 hours compared to baseline value (3.2 ± 0.8 mM vs. 2.0 ± 0.6 mM, p < 0.001). In addition, pH-value decreased from 7.34 ± 0.03 at baseline to 7.29 ± 0.03 after 2 hours (p < 0.001).

Discussion
Our study revealed that CNP and NT-proCNP are stable in serum and in full blood samples for at least two hours at room temperature. Consequently, the stability of the CNP peptide is most likely not affected by any delay in sample
processing for at least two hours. ProCNP has already been reported (manufacturer’s protocol, unknown storage conditions of blood samples) to be stable for at least 2.5 hours. Accordingly, our experiments confirmed the stability of NT-proCNP even at room temperature. The concentration of NT-proCNP in all sample types remained constant during the time course for up to 2 hours, indicating long lasting stability of this protein. As listed in Table 1, the mean concentration of NT-proCNP (56.5 ± 24.3 pg/ml) measured in this study was within the reported range (see Table 1) of healthy individuals (3.7-432 pg/ml).

In contrast to NT-proCNP, the concentration of CNP was significantly higher in plasma samples compared to serum and full blood samples (Figure 1). So far, neither our group nor manufacturers technical service found any evidence concerning the influence of sample type on the ELISA assay used in this study. However, at baseline, supernatant of plasma and full blood samples were identical with the exception of type of blood clotting inhibitor used. This inhibitor was sodium citrate in the plasma group and EDTA in the full blood sample group. Full blood samples revealed comparable results to serum samples (p = 0.98). Therefore, it is most likely that sodium citrate may significantly influence the measured concentration of CNP in plasma and consequently falsify the results achieved by this technique.

Unexpectedly, baseline concentrations of CNP in both plasma and serum samples were about a thousand-fold higher than in other reports (Table 1) [10-13,15,19]. In all of these studies the Radioimmunoassay (RIA-Kit) was used for the determination of CNP concentrations. In contrast, in two other studies the measured CNP concentrations in serum and plasma samples were comparable to our results with respect to the magnitude of dimension [16,22]. Interestingly, in the latter studies, the same ELISA-Kit was used as in our investigation. Even after extensive evaluation of various internal and external factors, no satisfied explanation of this discrepancy could be found. Control measurements using exogenous CNP in human serum revealed a non-significant measurement error of +7.8% (95%-KI: [−1.9%]−[+17.5%]). The CNP peptide used for the reference curve was synthesized by the manufacturer itself (Phoenix). In contrast, the CNP peptide used as the “exogenous” control was provided by Bachem. As assured by both manufacturers, sequences of amino acids were identical and disulfide bonds were formed in both peptides.

However, results of internal control measurements can be summarised as follows: First, the control measurements performed in our study revealed that the ELISA kits were used properly, in accordance with the manufacturer’s instructions. Second, measurements using control samples confirmed suitability of standard curve applied. Third, control serum samples containing exogenous CNP revealed acceptable accuracy and results were within the expected order of magnitude. Fourth, a higher concentration of CNP in plasma samples is most likely an artefact caused by sodium-citrate.

As reported by Clerico and co-workers, comparable great differences in results among different RIA and EIA methods are also known for, e.g. ANP and BNP [23-26]. Clerico and co-workers concluded that the large differences in these results are most likely due to the specificity of monoclonal or polyclonal antibodies used, the design of immunoassay system (competitive vs. non-competitive assay), the analytical matrix (serum vs. EDTA vs. heparinized plasma) used, and the plethora of circulating forms of natriuretic peptides, as previously reported for ANP and BNP immunoassays [23,26,27]. These methodological sources of bias may also be conceivable for CNP and NT-proCNP assays and thus explain the great difference in results in the cited studies (Table 1).

**Limitations of the study**

We acknowledge that a sample size of 12 is too small to conclude that there is no difference at all. However, from a statistical point of view, it would be important to specify how large the difference must be to be of medical relevance. To our knowledge, the latter is not yet clearly defined. Therefore, the means and 95%-confidence intervals of all measures were given in the figure to enable every reader to draw his own interpretation from the data as well.

In reference to serum and plasma concentrations, it must be mentioned that the values reported in Table 1 were measured with different methods (RIA, ELISA) in patients suffering from different diseases. It would have been very helpful to compare CNP-RIA with CNP-ELISA assays directly using the same specimens, because a thousandfold difference in the order of magnitude remains noticeable. Unfortunately, RIA assays measurements were not available in our laboratory. For NT-proCNP concentration, the latter comparison was investigated by Olney and co-workers[28] showing that the commercial ELISA (Biomedica Medizinprodukte GmbH & Co KG, Vienna, Austria) gave values that were an average of 21% (range 11-52%) of the RIA values. Cross-validation of the reference standard of the ELISA kit using RIA assay showed a disagreement of 15% [28].

**Summary**

Measurements of CNP and NT-proCNP were most likely unaffected by delay of sample procession or type of blood sample (except for CNP in plasma samples). For plasma samples, only EDTA anticoagulated blood samples were suitable for the CNP ELISA assay used in this study. Consequently, the concentration of CNP and NT-proCNP could be used in clinical applications in order to determine...
CNP effects. It should also be considered that the concentration of NT-proCNP, being only a by-product of the active peptide, may conceal the true nature of CNP. However, discrepancy in measured CNP concentrations determined either by RIA-arrays or by ELISA-assays still remains unexplained but seems most likely to be due to methodological issues. Therefore, as recommended for ANP and BNP [23], immunoassays for CNP need also to be standardized or harmonized in the future.

Competing interests
All authors declare that they have no competing interests.

Authors’ contributions
AK: Study design, acquisition of data, data analysis/interpretation, drafting the manuscript. JP: Study design, acquisition of data, critical revision of the draft. MB: acquisition of data, drafting the manuscript. WS: acquisition of data, drafting the manuscript. ALL: Final approval of the manuscript.

Acknowledgements
We would like to thank Mrs. Renate Hegenholz and Mrs. Mihaela Culmes for their excellent technical support. In addition, we thank all referees for their valuable comments and helpful suggestions.

Received: 8 November 2012 Accepted: 6 March 2013
Published: 1 April 2013

References
1. Inoue Y, Naruse K, Yamagami S, Mitani H, Suzuki N, Takei Y: Four functionally distinct C-type natriuretic peptides found in fish reveal evolutionary history of the natriuretic peptide system. Proc Natl Acad Sci U S A 2003, 100:10070–10074.
2. Pagel-Langenickel I, Buttgereit J, Bader M, Langenickel TH: Natriuretic peptide receptor B signaling in the cardiovascular system: protection from cardiac hypertrophy. J Mol Med 2007, 85:797–810.
3. Anand-Srivastava MB: Natriuretic peptide receptor-C signaling and regulation. Peptides 2005, 26:1044–1059.
4. Pelsie J, Kuehnl A, Rolland PH, Meckau I, Fuchs A, Walker GF, Ogris A, Wagner E, Nikol S: Functional analysis of genomic DNA, cDNA, and nucleotide sequence of the mature C-type natriuretic peptide gene in vascular cells. Arterioscler Thromb Vasc Biol 2004, 24:1646–1651.
5. Simon A, Harrington EO, Liu G, Keren G, Chouchard C: Mechanism of C-type natriuretic peptide-induced endothelial cell hyperpolarization. Am J Physiol Lung Cell Mol Physiol 2009, 296:L248–L256.
6. Pelsie J, Fuchs AT, Kuehnl A, Tian W, Kuhlmann MT, Rolland PH, Meckau I, Gaedtke L, Nikol S: C-type natriuretic peptide for reduction of restenosis: gene transfer is superior over single peptide administration. J Gene Med 2006, 8(12):S5–S9.
7. Kühnl A, Pelsie J, Tian W, Kuhlmann M, Rolland PH, Meckau I, Fuchs A, Nikol S: C-type natriuretic peptide inhibits contractive remodeling without compromising re-endothelialization in balloon-dilated renal arteries. J Endovasc Ther 2005, 12:171–182.
8. Casco VH, Veinot JP, Kurosaki de Bold ML, Masters RG, Stevenson MM, de Bold AJ: Natriuretic peptide system gene expression in human coronary arteries. J Histochem Cytochem 2002, 50:799–809.
9. Kuehnl A, Pelsie J, Pongratz J, Eckstein HH: C-Type Natriuretic Peptide and its Receptors in Atherosclerotic Plaques of the Carotid Artery of Clinically Asymptomatic Patients. Eur J Vasc Endovasc Surg 2012, 43(6):649–54.
10. Del Ry S, Cavanti M, Stefano T, Catapano G, Clerici A, Emdin M, Giannessi D: Measurement of cardiac natriuretic peptide: a review. Clin Chim Acta 2008, 406:1054–1065.
11. Del Ry S, Cantoni M, Cabiati M, Cavanti M, Cortis S, Prescimone T, Muzi B, Clerico A, Giannessi D: Amino-terminal pro-C-type natriuretic peptide in healthy children. Pediatr Nephrol 2012, 33:83–86.
12. Del Ry S, Giannessi D, Maltinti M, Prontera C, Iervasi A, Caltioli C, Emdin M, L’Abbate A, Neglia D: Increased levels of C-type natriuretic peptide in patients with idiopathic left ventricular dysfunction. Peptides 2007, 28:1068–1073.
13. Del Ry S, Passino C, Maltinti M, Emdin M, Giannessi D: C-type natriuretic peptide plasma levels increase in patients with chronic heart failure as a function of clinical severity. Eur J Heart Fail 2005, 7:1145–1148.
14. Dietmann A, Lackner P, Hellbok R, Spora K, Issioul S, Leil B, Reinli M, Kremers PG, Schmutzhard E: Opposed circulating plasma levels of endothelin-1 and C-type natriuretic peptide in children with Plasmoidium falciparum malaria. Malar J 2008, 7:253.
15. Gulberg V, Moller S, Henriksen JH, Gerbes AL: Increased renal production of C-type natriuretic peptide (CNP) in patients with cirrhosis and functional renal failure. Gut 2000, 47:852–857.
16. Luptaletti G, Marchesi S, Siepi D, Bagaglia F, Palumbo B, Boscini AR, Schlacci G, Vaudo G, Sinzinger H, Mannarino E: Natriuretic peptides levels are related to HDL-cholesterol with no influence on endothelium dependent vasodilation. Vasa 2006, 35:215–220.
17. Olewičz-Gawelik A, Danzak-Pazdrowika A, Klamka K, Silny W, Prokop J, Mackiewicz S, Gala P, Hyacja P: Blood serum levels of amino-terminal pro-C-type natriuretic peptide in patients with systemic sclerosis. Connect Tissue Res 2010, 51:83–87.
18. Olney RC, Prickett TC, Yandle TG, Espiner EA, Han JC, Mauers N: Amino-terminal propeptide of C-type natriuretic peptide and linear growth in children: effects of puberty, testosterone, and growth hormone. J Clin Endocrinol Metab 2007, 92:4294–4298.
19. Palmieri SC, Prickett TC, Espiner EA, Yandle TG, Richards AM: Regional release and clearance of C-type natriuretic peptides in the human circulation and relation to cardiac function. Hypertension 2009, 54:612–618.
20. Prickett TC, Yandle TG, Nicholls MG, Espiner EA, Richards AM: Identification of amino-terminal pro-C-type natriuretic peptide in human plasma. Biochem Biophys Res Commun 2001, 286:513–517.
21. Vigourous C, Ioakeimidis N, Terentes-Printzios D, Rokkas K, Aznaouridis K, Boui K, Bratas A, Fassoulakis C, Stefanadis C: Amino-terminal pro-C-type natriuretic peptide is associated with the presence, severity, and duration of vasculogenic erectile dysfunction. Eur Urol 2009, 56:552–558.
22. Yagi R, Toton Y, Ooku E, Ohto H, Hakky G, Esigli M: Serum levels of natriuretic peptides in patients with Behcet’s disease. Clin Rheumatol 2008, 27:1153–1158.
23. Clerico A, Del Ry S, Giannessi D: Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptides) in clinical practice: the need for a new generation of immunoassay methods. Clin Chim Acta 2000, 46:1529–1534.
24. Clerico A, Emdin M: Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin Chem 2004, 50:53–50.
25. Clerico A, Zaninotto M, Prontera C, Giovannini S, Ndreu R, Franzini M, Zuccelli GC, Plebani M, Study Group on Cardiovascular Risk Biomarkers of the Italian Society of Clinical B: State of the art of BNP and NT-proBNP immunoassays: the CardioOmoCheck study. Clin Chimica acta; international journal of clinical chemistry 2012, 414:112–119.
26. Clerico A, Vittorini S, Prontera C: Circulating forms of the B-type natriuretic peptide prohormone: pathophysiological and clinical considerations. Adv Clin Chem 2012, 58:31–44.
27. Emdin M, Passino C, Clerico A: Natriuretic peptide assays revisited: do we need pro-B-type natriuretic peptide? J Am Coll Cardiol 2011, 57:1396–1398.
28. Olney RC, Pernuy JW, Prickett TC, Han JC, Espiner EA: Amino-terminal propeptide of C-type natriuretic peptide (NT-proCNP) predicts height velocity in healthy children. Clin Endocrinol (Oxf) 2012, 77:416–422.